Genome editing portfolio Biomay’s expansion into mRNA-encoded spCas9 and optimized nuclease variants creates opportunities to target biotech firms and research labs needing ready-to-use genome editing tools, enabling faster procurement cycles and co-development potential.

Contract manufacturing scale As a GMP manufacturer with facilities expansion in Vienna, Biomay can position itself as a reliable partner for plasmid DNA, mRNA, and recombinant proteins for clients scaling from early development to commercial production, appealing to mid-size biotechs seeking reliable supply.

Strategic partnerships Past collaborations with BioNTech and chromatography partners indicate openness to joint development and large-scale supply agreements; sales outreach can emphasize long-term supply contracts, quality assurance, and manufacturing scalability for vaccine and gene therapy programs.

Quality and compliance Biomay highlights GMP focus and reliability; selling points include validated processes, regulatory readiness, and high-purity products for CRISPR components and plasmids, addressing customer demands for audit-ready manufacturing and documentation.

Global reach in Europe Vienna-based operations position Biomay as a Western Europe regional supplier with potential to serve nearby European biotech clusters, enabling targeted outreach to companies seeking local manufacturing partners with robust supply assurance.